Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Wounds and Injuries

Rare Diseases

Acute Kidney Injury

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Renal Insufficiency

Kidney Diseases

Urologic Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Acute Graft Versus Host Disease

haemodiafiltration with ultrafiltrate regeneration by adsorption on resin (HFR-SUPRA) combined with chemotherapy. HFR-SUPRA everyday for 3 days, then 3 times per week.

hemodialysis combined with chemotherapy. Hemodialysis everyday for 3 days, then 3 times per week.

HFR-SUPRA everyday for 3 days, then 3 times/week until patients do not require dialysis.

HFR-SUPRA

hemodialysis everyday for 3 days, then 3 times/week until patients do not require dialysis.

hemodialysis

chemotherapy protocol will be made by hematologists.

Chemotherapy

SanXi Ai, MD

Yan Qin, MD

In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.

In patients with multiple myeloma-related severe acute kidney injury, compare the renal outcome between patients receiving HFR-SUPRA and patients receiving hemodialysis. Both groups of patients receive chemotherapy.

Patients are divided into two groups: (1) chemotherapy combined with HFR-SUPRA (2) chemotherapy combined with hemodialysis

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study

independence from dialysis at 90 days from allocation to groups

independence from dialysis at 6 months from allocation to groups

serum creatinine elevation≤ 0.2 mg/dl from baseline or serum creatinine ≤ 1.2 mg/dl if baseline level is unknown

decline of free light chain from baseline level

hematological remission at 90 days from allocation to groups

hematological remission at 6 months from allocation to groups

Spots Global Cancer Trial Database for hemodiafiltration with ultrafiltrate regeneration (hfr)